Adeno-associated Virus (AAV) CDMO Solutions

We deliver comprehensive contract development and manufacturing organization (CDMO) services for advanced therapeutics, with specialized expertise in adeno-associated virus (AAV) platforms. Our integrated approach accelerates the development pathway from concept to application, supporting innovators in navigating complex biological and regulatory landscapes. Discover our full spectrum of capabilities in CDMO Solutions and Viral Vector CDMO Solutions.

Understanding AAV

AAV vectors have emerged as leading vehicles for gene-based therapeutic interventions due to their favorable safety characteristics, sustained expression profiles, and adaptable tissue targeting. As naturally non-pathogenic viral systems, they enable efficient genetic payload delivery without genomic integration risks. Their diverse serotype library permits precise tissue tropism customization. Our deep understanding of AAV biology, coupled with advanced manufacturing science, positions us to ensure the development of robust and scalable production platforms. These platforms are designed to align with the stringent quality expectations set by global regulatory authorities, ultimately fostering the advancement of gene therapies that can safely and effectively benefit patients.

Our AAV CDMO Solutions

Vector Design and Engineering Expertise

Our bioinformatics-driven design platform integrates structural modeling, immunogenicity prediction, and tropism analysis to engineer optimized AAV constructs. Through iterative design-build-test cycles, we accelerate the development of vectors with improved transduction efficiency and reduced immunogenicity. We offer:

Capsid Engineering: Custom modifications to evade neutralizing antibodies and enhance target specificity.
Promoter/Transgene Optimization: Tissue-specific expression systems and codon optimization strategies.
Library Screening: Access to natural and engineered serotype variants for optimal biodistribution.

Advanced Process Development

Our platform approach bridges early-stage development to commercial readiness:

Upstream Innovation: High-density suspension culture systems with optimized transfection and feeding strategies
Downstream Purity: Multi-modal chromatography and filtration technologies for efficient separation of full/empty capsids
Scalability: Seamless process transfer from benchtop to production scale through parameter optimization
Platform Analytics: Rapid analytical methods enabling real-time process decisions

GMP Manufacturing

Our flexible manufacturing infrastructure supports end-to-end production:

Scale Flexibility: Dedicated suites for clinical and commercial volumes.
Technology Platforms: Adherent and suspension systems with advanced production controls.
Quality Integration: In-process analytics embedded within manufacturing workflows.
Supply Chain Control: Integrated plasmid production ensuring material traceability.

Comprehensive Analytical Support

Our quality-by-design approach includes:

Characterization Suite: Physicochemical, biological, and immunological profiling.
Safety Testing: Comprehensive adventitious agent and impurity clearance validation.
Stability Management: Real-time and accelerated stability protocols.
Comparability Frameworks: Orthogonal methods for process change assessments.

Fill-Finish and Packaging Solutions

Our integrated capabilities encompass:

Formulation Expertise: Stability-optimized buffers for liquid and lyophilized products.
Aseptic Processing: Automated filling under controlled environments.

Frequently Asked Questions

Q1: How do you address immunogenicity challenges in AAV therapies?

Our multi-faceted approach combines capsid engineering to reduce immune recognition, proprietary purification methods to eliminate empty capsids, and comprehensive preclinical screening for complement activation and cytokine responses.

Q2: What scalability advantages does your platform provide?

Our modular platform enables linear scale-up without process re-optimization. Standardized technologies across scales ensure consistent product quality while reducing tech transfer timelines.

Q3: Can you support projects requiring novel capsid variants?

We maintain an extensive library of natural and engineered serotypes. Our biodistribution screening platform identifies optimal vectors for specific tissue targets, including challenging sites.

Our products and services are for research use only.